Meropenem-vaborbactam is a novel antibiotic combination of a carbapenem with a broad-spectrum beta-lactamase inhibitor that potently inhibits certain carbapenemases. In a randomized trial of patients with complicated urinary tract infection, including pyelonephritis, clinical and microbiologic outcomes were comparable between meropenem-vaborbactam and piperacillin-tazobactam . The main role of meropenem-vaborbactam is for treatment of infections with highly resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae; data evaluating outcomes with such organisms are limited but emerging

Speaker slots available :https://asiapacific.pharmaceuticalconferences.com/